Skip to main content
Premium Trial:

Request an Annual Quote

PredxBio: Brad Spitz

Brad Spitz has been appointed as chief commercial officer of PredxBio. Prior to joining the Pittsburgh-based spatial biology software company, he spent 19 years at Johnson & Johnson, where he held various roles at Ethicon, Ortho-Clinical Diagnostics, Veridex, and Janssen Diagnostics. He also held VP of sales positions at Angle, Orbis Biosciences, and Congenica. Spitz holds an MBA from Elon University and a bachelor's degree in economics and communications from the University of Wisconsin, Madison.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.